Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 77, Issue 4, Pages 706-712Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.06.032
Keywords
basal cell carcinoma; bone marrow transplantation; hematopoietic cell transplantation; nonmelanoma skin cancer; squamous cell carcinoma; voriconazole
Categories
Funding
- National Cancer Institute Cancer Center Support Grant [5P30CA124435]
- Stanford National Institutes of Health/National Center for Research Resources Clinical and Translational Science Award [UL1 RR025744]
Ask authors/readers for more resources
Background: Voriconazole has previously been associated with increased risk for cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients. Less is known about the risk in patients after hematopoietic cell transplantation (HCT). Objective: We evaluated the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcionoma, among those who have undergone allogeneic and autologous HCT. Methods: In all, 1220 individuals who had undergone allogeneic HCT and 1418 who had undergone autologous HCT were included in a retrospective cohort study. Multivariate analysis included voriconazole exposure and other known risk factors for NMSC. Results: In multivariate analysis, voriconazole use increased the risk for NMSC (hazard ratio, 1.82; 95% confidence interval, 1.13-2.91) among those who had undergone allogeneic HCT, particularly for SCC (hazard ratio, 2.25; 95% confidence interval, 1.30-3.89). Voriconazole use did not appear to confer increased risk for NMSC among those who had undergone autologous HCT. Limitations: This is a retrospective study. Conclusion: Voriconazole use represents an independent factor that may contribute to increased risk specifically for SCC in the allogeneic HCT population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available